Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2009, Vol. 3 Issue (3) : 256-264     DOI: 10.1007/s11684-009-0052-3
Research articles |
Molecular targeted therapy of gynecological malignant tumors: the development and challenge, from laboratory to clinic
Pengming SUN PhD, MD 1, Jalid SEHOULI PhD, MD 2, Lihui WEI BM 3,
1.Institute of Gynecologic Oncology, Fujian Provincial Women and Children''s Hospital, Fujian Medical University, Fuzhou 350001, China;Department of Gynecology, Campus Virchow Klinikum, Berlin 13353, Germany; 2.Department of Gynecology, Campus Virchow Klinikum, Berlin 13353, Germany; 3.Department of Gynecology, Peking University People’s Hospital, Beijing 100044, China;
Download: PDF(274 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  More and more molecular drugs based on targeted therapy have been utilized in the treatment of gynecologic cancer, especially in ovarian cancer. In this article, we systematically review the current targeted therapeutic trials running in clinic. Large, randomized trials have been conducted in the treatment of ovarian cancer, endometrial cancer and cervical cancer by using small molecule, antisense, mutational gene as well as antibodies. Other planned or ongoing trials currentlytargeted at molecular markers which may play important roles in gynecological carcinogenesis andprogression suggest that combination chemotherapy with molecular targeted therapy will ultimately be an importantoption.
Keywords target therapy      gynecologic malignant tumors      clinical trail      molecular medicine      
Issue Date: 05 September 2009
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0052-3     OR     http://academic.hep.com.cn/fmd/EN/Y2009/V3/I3/256
Rosner B A, Colditz G A, Webb P M, Hankinson S E. Mathematical models of ovarian cancer incidence. Epidemiology, 2005, 16(4): 508―515

doi: 10.1097/01.ede.0000164557.81694.63
Novac L,Grigore T , Cernea N, Niculescu M, Cotarcea S. Incidence of endometrialcarcinoma in patients with endometrial hyperplasia. Eur J Gynaecol Oncol, 2005, 26(5): 561―563
Katz I T, Wright A A. Preventing cervical cancerin the developing world. N Engl J Med, 2006, 354(11): 1110

doi: 10.1056/NEJMp068031
Farley J H, Birrer M J. Biologic directed therapiesin gynecologic oncology. Curr Oncol Rep, 2003, 5(6): 459―467

doi: 10.1007/s11912-003-0006-x
Qian C, Prieto J. Gene therapy of cancer: inductionof anti-tumor immunity. Cell Mol Immunol, 2004, 1(2): 105―111
Copland M, Jorgensen H G, Holyoake T L. Evolving molecular therapy for chronic myeloid leukaemia--arewe on target? Hematology, 2005, 10(5): 349―359

doi: 10.1080/10245330500234195
Stipsanelli E, Valsamaki P. Monoclonal antibodies: oldand new trends in breast cancer imaging and therapeutic approach. Hell J Nucl Med, 2005, 8(2): 103―108
Zhang Z, Li M, Rayburn E R, Hill D L, Zhang R, Wang H. Oncogenesas novel targets for cancer therapy (part II): Intermediate signalingmolecules. Am J Pharmacogenomics, 2005, 5(6): 247―257

doi: 10.2165/00129785-200505040-00005
Sharma S, Odunsi K. Targeted therapy for epithelialovarian cancer. Expert Opin Ther Targets, 2005, 9(3): 501―513

doi: 10.1517/14728222.9.3.501
Hyde J, McMeekin D S. Targeted therapies for gynecologicmalignancies. Curr Treat Options Oncol, 2005, 6(2): 121―132

doi: 10.1007/s11864-005-0020-3
Kumar R, Hung M C. Signaling intricacies takecenter stage in cancer cells. Cancer Res, 2005, 65(7): 2511―2515

doi: 10.1158/0008-5472.CAN-05-0189
Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis-thep53 network. J Cell Sci, 2003, 116(20): 4077―4085

doi: 10.1242/jcs.00739
Hanahan D, Weinberg R A. The hallmarks of cancer. Cell, 2000, 100(1): 57―70

doi: 10.1016/S0092-8674(00)81683-9
Sanseverino F, Torricelli M, Petraglia F, Giordano A. Roleof the retinoblastoma family in gynecological cancer. Cancer Biol Ther, 2003, 2(6): 636―641
Crowe D L, Kim R, Chandraratna R A. Retinoic acid differentially regulatescancer cell proliferation via dose-dependent modulation of the mitogen-activatedprotein kinase pathway. Mol Cancer Res, 2003, 1(7): 532―540
Katayama K, Dobashi Y, Kitagawa M, Kawai M, Kadoya Y, Kameya T. Cdk4/cyclinD1 kinase, a universal and critical regulator of apoptosis. Anticancer Res, 2003, 23(1A): 235―243
Mammas I N, Zafiropoulos A, Spandidos D A. Involvement of the ras genes in female genital tractcancer. Int J Oncol, 2005, 26(5): 1241―1255
Wang Y, Kristensen G B, Helland A, Nesland J M, Borresen-Dale A L, Holm R. Protein expression and prognostic value of genes in theerb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol, 2005, 124(3): 392―401

doi: 10.1309/BL7EMW66LQX6GFRP
Hennessy B T, Smith D L, Ram P T, Lu Y, Mills G B. Exploiting the PI3K/AKT pathway for cancerdrug discovery. Nat Rev Drug Discov, 2005, 4(12): 988―1004

doi: 10.1038/nrd1902
Thomas G V. mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev, 2006, 16(1): 78―84

doi: 10.1016/j.gde.2005.12.003
Choo A Y, Blenis J. TORgeting oncogene addictionfor cancer therapy. Cancer Cell, 2006, 9(2): 77―79

doi: 10.1016/j.ccr.2006.01.021
Chen H, Ye D, Xie X, Chen B, Lu W. VEGF, VEGFRs expressions and activated STATs in ovarianepithelial carcinoma. Gynecol Oncol, 2004, 94(3): 630―635

doi: 10.1016/j.ygyno.2004.05.056
Hirano T, Shino Y, Saito T, Komoda F, Okutomi Y, Takeda A, Ishihara T, Yamaguchi T, Saisho H, Shirasawa H. Dominantnegative MEKK1 inhibits survival of pancreatic cancer cells. Oncogene, 2002, 21(38): 5923―5928

doi: 10.1038/sj.onc.1205643
Silver D L, Naora H, Liu J, Cheng W, Montell D J. Activated signal transducer and activatorof transcription (STAT) 3: localization in focal adhesions and functionin ovarian cancer cell motility. CancerRes, 2004, 64(10): 3550―3558

doi: 10.1158/0008-5472.CAN-03-3959
Wang S C, Hung M C. HER2 overexpression and cancertargeting. Semin Oncol, 2001, 28(5 Suppl 16): 115―124

doi: 10.1053/sonc.2001.28553
Mizuki M, Ueda S, Matsumura I, Ishiko J, Schwable J, Serve H, Kanakura Y. Oncogenicreceptor tyrosine kinase in leukemia. CellMol Biol (Noisy-le-grand), 2003, 49(6): 907―922
Hu W, Kavanagh J J. Anticancer therapy targetingthe apoptotic pathway. Lancet Oncol, 2003, 4(12): 721―729

doi: 10.1016/S1470-2045(03)01277-4
Leonard J V, Schapira A H. Mitochondrial respiratorychain disorders I: mitochondrial DNA defects. Lancet, 2000, 355(9200): 299―304

doi: 10.1016/S0140-6736(99)05225-3
Sherbet G V, Patil D. Genetic abnormalities ofcell proliferation, invasion and metastasis, with special referenceto gynaecological cancers. Anticancer Res, 2003, 23(2B): 1357―1371
Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer, 2005, 5(4): 275―284

doi: 10.1038/nrc1590
Sirotnak F M, Zakowski M F, Miller V A, Scher H I, Kris M G. Efficacy of cytotoxic agents againsthuman tumor xenografts is markedly enhanced by coadministration ofZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res, 2000, 6(12): 4885―4892
Gadducci A, Cosio S, Genazzani A R. Old and new perspectives in the pharmacological treatmentof advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapyand molecularly targeted therapies. CritRev Oncol Hematol, 2006, 58(3): 242―256

doi: 10.1016/j.critrevonc.2005.11.002
Sewell J M, Macleod K G, Ritchie A, Smyth J F, Langdon S P. Targeting the EGF receptor in ovariancancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). British J Cancer, 2002, 86(3): 456―462

doi: 10.1038/sj.bjc.6600058
Schilder R J, Sill M W, Chen X, Darcy K M, Decesare S L, Lewandowski G, Lee R B, Arciero C A, Wu H, Godwin A K. Phase II study of gefitinibin patients with relapsed or persistent ovarian or primary peritonealcarcinoma and evaluation of epidermal growth factor receptor mutationsand immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res, 2005, 11(15): 5539―5548

doi: 10.1158/1078-0432.CCR-05-0462
Gordon A N, Finkler N, Edwards R P, Garcia A A, Crozier M, Irwin D H, Barrett E. Efficacyand safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR)tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma:results from a phase II multicenter study. Int J Gynecol Cancer, 2005, 15(5): 785―792

doi: 10.1111/j.1525-1438.2005.00137.x
Xiong H Q, Herbst R, Faria S C, Scholz C, Davis D, Jackson E F, Madden T, McConkey D, Hicks M, Hess K, Charnsangavej C A, Abbruzzese J L. A phase I surrogate endpoint study of SU6668 in patientswith solid tumors. Invest New Drugs, 2004, 22(4): 459―466

doi: 10.1023/B:DRUG.0000036688.96453.8d
Del Carmen M G, Rizvi I, Chang Y, Moor A C, Oliva E, Sherwood M, Pogue B, Hasan T. Synergism of epidermal growth factor receptor-targetedimmunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst, 2005, 97(20): 1516―1524
Cohn D E, Valmadre S, Resnick K E, Eaton L A, CopelandL J, Fowler J M. Bevacizumab and weekly taxane chemotherapy demonstratesactivity in refractory ovarian cancer. Gynecol Oncol, 2006, 102(2): 131―133

doi: 10.1016/j.ygyno.2006.01.030
Bookman M A, Darcy K M, Clarke-Pearson D, Boothby R A, Horowitz I R. Evaluation of monoclonalhumanized anti-HER2 antibody, trastuzumab, in patients with recurrentor refractory ovarian or primary peritoneal carcinoma with overexpressionof HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol, 2003, 21(2): 283―290

doi: 10.1200/JCO.2003.10.104
Santin A D, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman J J, Hutchins L, Pecorelli S, O'Brien T, Cannon M J, Parham G P. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res, 2002, 8(5): 1271―1279
Oza A M, Elit L, Swenerton K, Faught W, Ghatage P, Carey M, McIntosh L, Dorr A, Holmlund J T, Eisenhauer E. PhaseII study of CGP 69846A (ISIS 5132) in recurrent epithelial ovariancancer: an NCIC clinical trials group study (NCIC IND.116). Gynecol Oncol, 2003, 89(1): 129―133

doi: 10.1016/S0090-8258(02)00144-0
Advani R, Peethambaram P, Lum B L, Fisher G A, Hartmann L, Long H J, Halsey J, Holmlund J T, Dorr A, Sikic B I. A Phase IItrial of aprinocarsen, an antisense oligonucleotide inhibitor of proteinkinase C alpha, administered as a 21-day infusion to patients withadvanced ovarian carcinoma. Cancer, 2004, 100(2): 321―326

doi: 10.1002/cncr.11909
Armstrong D K, Blessing J A, Look K Y, Schilder R, Nunez E R. A randomized phase II evaluationof bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitiveovarian cancer: a Gynecologic Oncology Group Study. Invest New Drugs, 2003, 21(3): 373―377

doi: 10.1023/A:1025490818450
Smith V, Hobbs S, Court W, Eccles S, Workman P, Kelland L R. ErbB2 overexpression in an ovarian cancer cell line conferssensitivity to the HSP90 inhibitor geldanamycin. Anticancer Res, 2002, 22(4): 1993―1999
Aghajanian C, Dizon D S, Sabbatini P, Raizer J J, Dupont J, Spriggs D R. Phase I trial of bortezomib and carboplatin in recurrentovarian or primary peritoneal cancer. JClin Oncol, 2005, 23(25): 5943―5949

doi: 10.1200/JCO.2005.16.006
Siu L L, Awada A, Takimoto C H, Piccart M, Schwartz B, Giannaris T, Lathia C, Petrenciuc O, Moore M J. Phase I trial of sorafenib and gemcitabine in advancedsolid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res, 2006, 12(1): 144―151

doi: 10.1158/1078-0432.CCR-05-1571
Buller R E, Runnebaum I B, Karlan B Y, Horowitz J A, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M. Aphase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrentovarian cancer. Cancer Gene Ther, 2002, 9(7): 553―566

doi: 10.1038/sj.cgt.7700472
Kavanagh J J, Gershenson D M, Choi H, Lewis L, Patel K, Brown G L, Garcia A, Spriggs D R. Multi-institutional phase 2 study of TLK286 (TELCYTA,a glutathione S-transferase P1-1 activated glutathione analog prodrug)in patients with platinum and paclitaxel refractory or resistant ovariancancer. Int J Gynecol Cancer, 2005, 15(4): 593―600

doi: 10.1111/j.1525-1438.2005.00114.x
Vasey P A, Shulman L N, Campos S, Davis J, Gore M, Johnston S, Kirn D H, O'Neill V, Siddiqui N, Seiden M V, Kaye S B. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deletedadenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeksin patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol, 2002, 20(6): 1562―1569

doi: 10.1200/JCO.20.6.1562
Geffen D B, Man S. New drugs for the treatmentof cancer, 1990-2001. Isr Med Assoc J, 2002, 4(12): 1124―1131
Libermann T A, Zerbini L F. Targeting transcription factorsfor cancer gene therapy. Curr Gene Ther, 2006, 6(1): 17―33

doi: 10.2174/156652306775515501
[1] Zhi Xu,Chunxiang Cao,Haiyan Xia,Shujing Shi,Lingzhi Hong,Xiaowei Wei,Dongying Gu,Jianmin Bian,Zijun Liu,Wenbin Huang,Yixin Zhang,Song He,Nikki Pui-Yue Lee,Jinfei Chen. Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma[J]. Front. Med., 2016, 10(1): 52-60.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed